Mirdametinib and abemaciclib cooperate in atypical teratoid rhabdoid tumor to decrease proliferation and suppress...

Area of Science:

• Pediatric Oncology
• Molecular Biology
• Pharmacology

Background:

• Atypical teratoid rhabdoid tumor (ATRT) is a rare and aggressive pediatric brain cancer with poor survival rates.
• The mitogen-activated protein (MAP) kinase pathway is frequently dysregulated in ATRT.

Purpose of the Study:

• To investigate the efficacy of mirdametinib, a novel MEK inhibitor, as a monotherapy and in combination with abemaciclib in ATRT.
• To evaluate the impact of these agents on ATRT cell proliferation and apoptosis.

Main Methods:

• In vitro studies using ATRT cell lines treated with mirdametinib.
• In vivo studies using orthotopic xenograft mouse models of ATRT treated with mirdametinib alone and in combination with abemaciclib.
• Assessment of proliferation (BrdU incorporation) and apoptosis (cPARP, Annexin V staining).

Main Results:

• Mirdametinib demonstrated potent inhibition of ATRT cell growth in vitro at nanomolar concentrations.
• Mirdametinib monotherapy extended survival in mice with ATRT xenografts.
• Combination therapy with mirdametinib and abemaciclib significantly suppressed proliferation and extended survival in preclinical ATRT models.

Conclusions:

• Mirdametinib exhibits single-agent activity against ATRT.
• Combination therapy with mirdametinib and abemaciclib represents a promising therapeutic strategy for ATRT, reducing proliferation and improving survival outcomes.